Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Judith Trotman; Sally F Barrington; David Belada; Michel Meignan; Robert Macewan; Carolyn Owen; Václav Ptáčn'Ik; András Rosta; Günter R Fingerle-Rowson; Jiawen Zhu; Tina Nielsen; Deniz Sahin; Wolfgang Hiddemann; Robert E Marcus; Andrew Davies; Mark Hertzberg; Andrew Grigg; Paul Cannell; Hang Quach; Stephen Opat; Constantine Tam; Paula Marlton; Ann Janssens; Fritz Offner; Koen van Eygen; Randeep Sangha; Pam Mckay; Jonathan Wilson; Richard van Der Jagt; Daryl Roitman; Marek Trneny; Jiri Mayer; Katell Le Du; Philippe Solal-Celigny; Guillaume Cartron; Charles Foussard; Norbert Frickhofen; Peter Schmidt; Ullrich Graeven; Tobias Gaska; Rudolf Schlag; Martin Sökler; Gabriele Prange-Krex; Axel Florschütz; Hans-Walter Lindemann; Christoph Schimmelpfennig; Solveig Tonndorf; Mathias Hänel; Georg Hess; Enrico Schalk; Heiko Hütten; Gottfried Doelken; Michael Pfreundschuh; Ulrich Keller; Michael Herold; Roswitha Forstpointner; Ursula Vehling-Kaiser; Martin Hoffmann; Zita Borbényi; Miklos Udvardy; Judit Demeter; Alessandro Rambaldi; Enrica Morra; Federico Massimo; Ignazio Majolino; Monica Balzarotti; Gianpietro Semenzato; Miguel Angel Canales Albendea; Francisco Javier Peñalver Parraga; Alfonso Soler Campos; Juan Manuel Sancho Cia; Jose Antonio Marquez Navarro; Carlos Grande Garcia; Herman Nilsson-Ehle; Helen Mccarthy; Chris Pocock; Shalal Sadullah; Ram Malladi; John Radford; Ed Kanfer; Anton Kruger; Dominic Culligan; Martin Dyer; Ruth Pettengell; John Seymour; John Gribben; Saad Al-Ismail; Faris Al-Refaie; Norbert Blesing; Christopher Macnamara; Ann O'Callaghan; Andrew Haynes; George Follows; Roderick Johnson; David Cunningham; Kristian Bowles; Graham Collins; Eve Gallop-Evans; Stephen Robinson; Chezhian Subash; James Bailey; Viran Holden; Jeffrey Neidhart; Moacyr de Oliveira; Haluk Tezcan; Kevin Kim; Suman Kambhampati; Keith Lanier; John Mcclean; Kensei Tobinai

doi:10.1016/S1470-2045(18)30618-1

Back

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Journal article

Open access

Peer reviewed

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Judith Trotman, Sally F Barrington, David Belada, Michel Meignan, Robert Macewan, Carolyn Owen, Václav Ptáčn'Ik, András Rosta, Günter R Fingerle-Rowson, Jiawen Zhu, …

Lancet Oncology, Vol.19(11), pp.1530--1542

2018

DOI: https://doi.org/10.1016/S1470-2045(18)30618-1

Abstract

PET investigators from the GALLIUM study (2018). Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. The Lancet Oncology.

Files and links (1)

url

Find in HALView

Metrics

1 Record Views

See more details

Details

Title: Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial
Creators - without role: Judith Trotman - University of Sydney
Sally F Barrington - Kings Health Partners
David Belada - University of Hradec Králové
Michel Meignan - Université Paris-Est Créteil
Robert Macewan - University of Alberta
Carolyn Owen - Foothills Medical Centre
Václav Ptáčn'Ik
András Rosta - National Institute of Oncology
Günter R Fingerle-Rowson - Roche
Jiawen Zhu
Tina Nielsen - Roche
Deniz Sahin - Roche
Wolfgang Hiddemann - Ludwig-Maximilians-Universität München
Robert E Marcus - King's College Hospital
Andrew Davies - Cancer Research UK
Mark Hertzberg - Neuroscience Research Australia
Andrew Grigg - Cancer Research UK
Paul Cannell
Hang Quach
Stephen Opat
Constantine Tam - National Institute of Oncology
Paula Marlton
Ann Janssens - LMU Klinikum
Fritz Offner - Ghent University
Koen van Eygen
Randeep Sangha
Pam Mckay
Jonathan Wilson
Richard van Der Jagt
Daryl Roitman
Marek Trneny
Jiri Mayer
Katell Le Du
Philippe Solal-Celigny
Guillaume Cartron - Service d'hématologie et oncologie médicale
Charles Foussard
Norbert Frickhofen
Peter Schmidt
Ullrich Graeven
Tobias Gaska
Rudolf Schlag
Martin Sökler
Gabriele Prange-Krex
Axel Florschütz
Hans-Walter Lindemann
Christoph Schimmelpfennig
Solveig Tonndorf
Mathias Hänel
Georg Hess
Enrico Schalk
Heiko Hütten
Gottfried Doelken
Michael Pfreundschuh
Ulrich Keller
Michael Herold
Roswitha Forstpointner
Ursula Vehling-Kaiser
Martin Hoffmann
Zita Borbényi
Miklos Udvardy
Judit Demeter - Concord Repatriation General Hospital
Alessandro Rambaldi
Enrica Morra
Federico Massimo
Ignazio Majolino
Monica Balzarotti
Gianpietro Semenzato
Miguel Angel Canales Albendea
Francisco Javier Peñalver Parraga
Alfonso Soler Campos
Juan Manuel Sancho Cia
Jose Antonio Marquez Navarro
Carlos Grande Garcia
Herman Nilsson-Ehle
Helen Mccarthy
Chris Pocock
Shalal Sadullah
Ram Malladi - Queen Elizabeth Hospital Birmingham
John Radford
Ed Kanfer
Anton Kruger
Dominic Culligan
Martin Dyer
Ruth Pettengell
John Seymour - University of Melbourne
John Gribben - Queen Mary University of London
Saad Al-Ismail
Faris Al-Refaie
Norbert Blesing
Christopher Macnamara
Ann O'Callaghan
Andrew Haynes - Cancer Research UK
George Follows
Roderick Johnson
David Cunningham - University of Hradec Králové
Kristian Bowles
Graham Collins
Eve Gallop-Evans
Stephen Robinson
Chezhian Subash
James Bailey - Parks Victoria
Viran Holden
Jeffrey Neidhart
Moacyr de Oliveira
Haluk Tezcan
Kevin Kim
Suman Kambhampati
Keith Lanier
John Mcclean
Kensei Tobinai
Publication Details: Lancet Oncology, Vol.19(11), pp.1530--1542
Identifiers: 9944564109311
Academic Unit: Institut de Génétique Moléculaire de Montpellier - IGMM
Language: English
Resource Type: Journal article
Local Fields: hal-02315103